查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1269441

末稍血管擴張藥市場- 全球產業分析，規模，佔有率，成長，趨勢，及預測，2023-2031年

Peripheral Vasodilator Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

末稍血管擴張藥市場- 調查範圍:

TMR 的研究報告《全球末稍血管擴張藥市場》為了提供2023年～2031年預測期間上關於市場指標的寶貴知識和見解，不僅探討了過去的增長趨勢，還調查了當前的增長趨勢和機會。本報告以 2023 年為基準年，2031 年為預測年。提供2017年到2031年的全球末稍血管擴張藥市場收益。並刊載2023年2031年的全球末稍血管擴張藥市場年複合成長率。

本報告透過廣泛研究作成。初步研究中由分析師對主要意見領袖、行業領袖和輿論製造者進行訪談，並進行大部分研究工作。二次研究則參考主要公司的產品資料、年報、新聞稿和相關文件，來掌握末稍血管擴張藥市場。

該報告深入探討全球末稍血管擴張藥市場的競爭格局。鎖定全球末稍血管擴張藥市場活動的主要企業，並對每家公司進行了不同屬性的分析。介紹企業概要，財務狀況，最近的趨勢，SWOT等全球末稍血管擴張藥市場企業的屬性。

目錄

第1章 序文

  • 市場定義和範圍
  • 市場區隔
  • 主要的調查目的
  • 調查亮點

第2章 前提條件與調查手法

第3章 摘要整理:全球市場

第4章 市場概要

  • 簡介
    • 定義
    • 產業的演進與發展
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 全球市場的分析與預測，2017-2031年
    • 市場收益預測

第5章 主要洞察

  • 全球疾病盛行率及發病率(各主要國家
  • 各地區/世界各國的法規Scenario
  • COVID-19疫情對產業的影響

第6章 全球市場分析·預測:各藥物類型

  • 簡介和定義
  • 主要的發現與發展
  • 市場價值預測:各藥物類型，2017-2031年
    • 鈣拮抗劑
    • 直接作用型血管擴張藥
    • α-腎上腺素阻斷劑
    • 鉀流通管道活性化劑
    • 硝酸藥
    • 其他
  • 市場魅力分析:各藥物類型

第7章 全球市場分析·預測:各流通管道

  • 簡介&定義
  • 主要調查結果·發展情形
  • 市場價值預測:各流通管道，2017-2031年
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場魅力分析:各流通管道

第8章 全球市場分析·預測:各地區

  • 主要調查結果
  • 市場規模預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲地區
  • 市場魅力分析:各地區

第9章 北美市場分析·預測

  • 簡介
    • 主要調查結果
  • 市場價值預測:各藥物類型，2017-2031年
    • 鈣拮抗劑
    • 直接作用型血管擴張藥
    • α-腎上腺素阻斷劑
    • 鉀流通管道活性化劑
    • 硝酸藥
    • 其他
  • 市場價值預測:各流通管道，2017-2031年
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場價值預測:各國，2017-2031年
    • 美國
    • 加拿大
  • 市場魅力分析
    • 各藥物類型
    • 各流通管道
    • 各國

第10章 歐洲市場分析與預測

  • 簡介
    • 主要調查結果
  • 市場價值預測:各藥物類型，2017-2031年
    • 鈣拮抗劑
    • 直接作用型血管擴張藥
    • α-腎上腺素阻斷劑
    • 鉀流通管道活性化劑
    • 硝酸藥
    • 其他
  • 市場價值預測:各流通管道，2017-2031年
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場價值預測:國家·小各地區，2017-2031年
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲
  • 市場魅力分析
    • 各藥物類型
    • 各流通管道
    • 各國/輔助region

第11章 亞太地區的市場分析與預測

  • 簡介
    • 主要調查結果
  • 市場價值預測:各藥物類型，2017-2031年
    • 鈣拮抗劑
    • 直接作用型血管擴張藥
    • α-腎上腺素阻斷劑
    • 鉀流通管道活性化劑
    • 硝酸藥
    • 其他
  • 市場價值預測:各流通管道，2017-2031年
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場價值預測:國家·小各地區，2017-2031年
    • 中國
    • 日本
    • 印度
    • 澳洲·紐西蘭
    • 其他亞太地區
  • 市場魅力分析
    • 各藥物類型
    • 各流通管道
    • 各國/輔助region

第12章 南美的市場分析·預測

  • 簡介
    • 主要調查結果
  • 市場價值預測:各藥物類型，2017年～2031年
    • 鈣拮抗劑
    • 直接作用型血管擴張藥
    • α-腎上腺素阻斷劑
    • 鉀流通管道活性化劑
    • 硝酸藥
    • 其他
  • 市場價值預測:各流通管道，2017-2031年
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場價值預測:國家·小各地區，2017-2031年
    • 巴西
    • 墨西哥
    • 其他南美國家地區
  • 市場魅力分析
    • 各藥物類型
    • 各流通管道
    • 各國/輔助region

第13章 中東·非洲的市場分析與預測

  • 簡介
    • 主要調查結果
  • 市場價值預測:各藥物類型，2017-2031年
    • 鈣拮抗劑
    • 直接作用型血管擴張藥
    • α-腎上腺素阻斷劑
    • 鉀流通管道活性化劑
    • 硝酸藥
    • 其他
  • 市場價值預測:各流通管道，2017-2031年
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場金額預測:國家·小各地區，2017-2031年
    • GCC各國
    • 南非
    • 其他中東·非洲
  • 市場魅力分析
    • 各藥物類型
    • 各銷售管道
    • 各國/輔助region

第14章 競爭情形

  • 市場企業-競爭矩陣(企業各層級，不同企業規模)
  • 市場佔有率分析:各企業，2022年
  • 企業簡介
    • Pfizer, Inc.
    • Novartis AG
    • GSK plc
    • AstraZeneca
    • Merck & Co., Inc.
    • Sanofi
    • Bayer AG
    • Abbott Laboratories
    • Bristol-Myers Squibb Company
    • Boehringer Ingelheim International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Viatris, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Lupin
Product Code: TMRGL85487

Peripheral Vasodilator Drugs Market - Scope of Report:

TMR's report on the global peripheral vasodilator drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global peripheral vasodilator drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peripheral vasodilator drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the peripheral vasodilator drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peripheral vasodilator drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global peripheral vasodilator drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peripheral vasodilator drugs market.

The report delves into the competitive landscape of the global peripheral vasodilator drugs market. Key players operating in the global peripheral vasodilator drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global peripheral vasodilator drugs market profiled in this report.

Key Questions Answered in Global Peripheral Vasodilator Drugs Market Report:

  • What is the sales/revenue generated by peripheral vasodilator drugs across all regions during the forecast period?
  • What are the opportunities in the global peripheral vasodilator drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Peripheral Vasodilator Drugs Market - Research Objectives and Research Approach:

The comprehensive report on the global peripheral vasodilator drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global peripheral vasodilator drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global peripheral vasodilator drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Peripheral Vasodilator Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Disease Prevalence & Incidence Rate globally with key countries
  • 5.2. Regulatory Scenario by Region/globally
  • 5.3. COVID-19 Pandemics Impact on Industry

6. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Type, 2017-2031
    • 6.3.1. Calcium Channel Blockers
    • 6.3.2. Direct-acting Vasodilators
    • 6.3.3. Alpha-adrenergic Blockers
    • 6.3.4. Potassium Channel Activators
    • 6.3.5. Nitrates
    • 6.3.6. Others
  • 6.4. Market Attractiveness Analysis, by Drug Type

7. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Peripheral Vasodilator Drugs Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Peripheral Vasodilator Drugs Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Drug Type, 2017-2031
    • 9.2.1. Calcium Channel Blockers
    • 9.2.2. Direct-acting Vasodilators
    • 9.2.3. Alpha-adrenergic Blockers
    • 9.2.4. Potassium Channel Activators
    • 9.2.5. Nitrates
    • 9.2.6. Others
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Value Forecast, by Country, 2017-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Drug Type
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Peripheral Vasodilator Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Type, 2017-2031
    • 10.2.1. Calcium Channel Blockers
    • 10.2.2. Direct-acting Vasodilators
    • 10.2.3. Alpha-adrenergic Blockers
    • 10.2.4. Potassium Channel Activators
    • 10.2.5. Nitrates
    • 10.2.6. Others
  • 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Drug Type
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Peripheral Vasodilator Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Type, 2017-2031
    • 11.2.1. Calcium Channel Blockers
    • 11.2.2. Direct-acting Vasodilators
    • 11.2.3. Alpha-adrenergic Blockers
    • 11.2.4. Potassium Channel Activators
    • 11.2.5. Nitrates
    • 11.2.6. Others
  • 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Online Pharmacies
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Drug Type
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Peripheral Vasodilator Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Type, 2017-2031
    • 12.2.1. Calcium Channel Blockers
    • 12.2.2. Direct-acting Vasodilators
    • 12.2.3. Alpha-adrenergic Blockers
    • 12.2.4. Potassium Channel Activators
    • 12.2.5. Nitrates
    • 12.2.6. Others
  • 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.3.1. Hospital Pharmacies
    • 12.3.2. Retail Pharmacies
    • 12.3.3. Online Pharmacies
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Drug Type
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Peripheral Vasodilator Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Type, 2017-2031
    • 13.2.1. Calcium Channel Blockers
    • 13.2.2. Direct-acting Vasodilators
    • 13.2.3. Alpha-adrenergic Blockers
    • 13.2.4. Potassium Channel Activators
    • 13.2.5. Nitrates
    • 13.2.6. Others
  • 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.3.1. Hospital Pharmacies
    • 13.3.2. Retail Pharmacies
    • 13.3.3. Online Pharmacies
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Drug Type
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (by tier and size of companies)
  • 14.2. Market Share Analysis, by Company, 2022
  • 14.3. Company Profiles
    • 14.3.1. Pfizer, Inc.
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Novartis AG
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. GSK plc
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. AstraZeneca
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Merck & Co., Inc.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Sanofi
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Bayer AG
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Abbott Laboratories
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Bristol-Myers Squibb Company
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Boehringer Ingelheim International GmbH
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. Financial Overview
      • 14.3.10.4. SWOT Analysis
      • 14.3.10.5. Strategic Overview
    • 14.3.11. Teva Pharmaceutical Industries Ltd.
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Product Portfolio
      • 14.3.11.3. Financial Overview
      • 14.3.11.4. SWOT Analysis
      • 14.3.11.5. Strategic Overview
    • 14.3.12. Viatris, Inc.
      • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.12.2. Product Portfolio
      • 14.3.12.3. Financial Overview
      • 14.3.12.4. SWOT Analysis
      • 14.3.12.5. Strategic Overview
    • 14.3.13. Sun Pharmaceutical Industries Ltd.
      • 14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.13.2. Product Portfolio
      • 14.3.13.3. Financial Overview
      • 14.3.13.4. SWOT Analysis
      • 14.3.13.5. Strategic Overview
    • 14.3.14. Lupin
      • 14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.14.2. Product Portfolio
      • 14.3.14.3. Financial Overview
      • 14.3.14.4. SWOT Analysis
      • 14.3.14.5. Strategic Overview

List of Tables

  • Table 01: Global Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 02: Global Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 03: Global Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 05: North America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 06: North America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: Europe Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 08: Europe Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Asia Pacific Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 11: Asia Pacific Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: Asia Pacific Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Latin America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 14: Latin America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 15: Latin America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Middle East & Africa Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 17: Middle East & Africa Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18: Middle East & Africa Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Peripheral Vasodilator Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 03: Global Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 04: Global Peripheral Vasodilator Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 05: Global Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 06: Global Peripheral Vasodilator Drugs Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 07: Global Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 08: North America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 09: North America Peripheral Vasodilator Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 10: North America Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 11: North America Peripheral Vasodilator Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 12: North America Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 13: North America Peripheral Vasodilator Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 14: North America Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 15: Europe Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 16: Europe Peripheral Vasodilator Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 17: Europe Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 18: Europe Peripheral Vasodilator Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 19: Europe Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 20: Europe Peripheral Vasodilator Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 21: Europe Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 22: Asia Pacific Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 23: Asia Pacific Peripheral Vasodilator Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 24: Asia Pacific Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 25: Asia Pacific Peripheral Vasodilator Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 26: Asia Pacific Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 27: Asia Pacific Peripheral Vasodilator Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 28: Asia Pacific Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Latin America Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 30: Latin America Peripheral Vasodilator Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 31: Latin America Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 32: Latin America Peripheral Vasodilator Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: Latin America Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 34: Latin America Peripheral Vasodilator Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 35: Latin America Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 36: Middle East & Africa Peripheral Vasodilator Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Middle East & Africa Peripheral Vasodilator Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 38: Middle East & Africa Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 39: Middle East & Africa Peripheral Vasodilator Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 40: Middle East & Africa Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 41: Middle East & Africa Peripheral Vasodilator Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Middle East & Africa Peripheral Vasodilator Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 43: Global Peripheral Vasodilator Drugs Market Share Analysis, by Company, 2022